Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study.
Auteurs : Janssens A, Berneman ZN, Offner F, Snauwaert S, Mineur P, Vanstraelen G, Meers S, Spoormans I, Bron D, Vande Broek I, Van Bogaert C, De Beleyr B, Smet A, Nielsen L, Wapenaar R, André M Année : 2022 Journal : Clin Hematol Int